ARTICLE | Company News
Lexrite Labs other research news
April 22, 2002 7:00 AM UTC
Lexrite received a $500,000 Phase I SBIR grant from the National Cancer Institute to develop compounds that will bind to a selected tumor antigen on adenocarcinoma cells using its antibody conjugate t...